Multiple Roles of Tissue Plasminogen Activator in Schizophrenia Pathophysiology

Abstract

Schizophrenia, a disabling mental disorder, is characterized by brain atrophy, especially in the superior temporal gyrus and the medial temporal lobe, which includes the hippocampus and the amygdala. The model that better explains brain atrophy includes a trigger and a predisposing condition. The trigger is exemplified by illicit drugs or environmental stressors that promote release of substances harmful to the neurons, such as glucocorticoids or noradrenalin. Predisposed patients would have one or more conditions that impair neuronal plasticity and neurogenesis. Evidence indicates that abnormal tissue plasminogen activator (tPA) activity is an important predisposing condition. tPA plays an important role in synaptic regulation and plasticity, and in neurogenesis, being crucial to the biology of memory, learning, and emotions. Several biochemical abnormalities seen in schizophrenics are related to decreased levels or impaired activity of tPA, including deficient dopamine transmission at D1 receptors in the prefrontal cortex, impaired cleavage of a precursor of brain-derived neurotrophic factor into its mature form (mature brain-derived neurotrophic factor), abnormal N-methyl-d-aspartate receptor-mediated signaling, reduced Akt phosphorylation, and abnormal activation of reelin. Clinical conditions related to schizophrenia, such as hyperhomocysteinemia, insulin resistance, and type 2 diabetes mellitus are characterized by a loss of tPA function or decreased tPA levels. This article reviews how low levels or abnormal function of tPA are related to the pathogenesis of schizophrenia.

Keywords

tissue plasminogen activator - neurogenesis - schizophrenia - mechanism of action - pathophysiology

• References

• 1 Shenton ME, Dickey CC, Frumin M, McCarley RW. A review of MRI findings in schizophrenia. Schizophr Res 2001; 49 (1-2) 1-52
• 2 Sapolsky RM. Stress and plasticity in the limbic system. Neurochem Res 2003; 28 (11) 1735-1742
• 3 Toro CT, Deakin JF. Adult neurogenesis and schizophrenia: a window on abnormal early brain development?. Schizophr Res 2007; 90 (1-3) 1-14
• 4 Benarroch EE. Tissue plasminogen activator: beyond thrombolysis. Neurology 2007; 69 (8) 799-802
• 5 Melchor JP, Strickland S. Tissue plasminogen activator in central nervous system physiology and pathology. Thromb Haemost 2005; 93 (4) 655-660
• 6 Fujioka H, Dairyo Y, Yasunaga K, Emoto K. Neural functions of matrix metalloproteinases: plasticity, neurogenesis, and disease. Biochem Res Int 2012; 2012: 789083
• 7 Rossi C, Angelucci A, Costantin L , et al. Brain-derived neurotrophic factor (BDNF) is required for the enhancement of hippocampal neurogenesis following environmental enrichment. Eur J Neurosci 2006; 24 (7) 1850-1856
• 8 Jin K, Zhu Y, Sun Y, Mao XO, Xie L, Greenberg DA. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad Sci U S A 2002; 99 (18) 11946-11950
• 9 Nacher J, McEwen BS. The role of N-methyl-D-asparate receptors in neurogenesis. Hippocampus 2006; 16 (3) 267-270
• 10 Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003; 92 (8) 827-839
• 11 Pang PT, Teng HK, Zaitsev E , et al. Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science 2004; 306 (5695) 487-491
• 12 Yuan H, Vance KM, Junge CE , et al. The serine protease plasmin cleaves the amino-terminal domain of the NR2A subunit to relieve zinc inhibition of the N-methyl-D-aspartate receptors. J Biol Chem 2009; 284 (19) 12862-12873
• 13 Ito M, Nagai T, Kamei H , et al. Involvement of tissue plasminogen activator-plasmin system in depolarization-evoked dopamine release in the nucleus accumbens of mice. Mol Pharmacol 2006; 70 (5) 1720-1725
• 14 Karam CS, Ballon JS, Bivens NM , et al. Signaling pathways in schizophrenia: emerging targets and therapeutic strategies. Trends Pharmacol Sci 2010; 31 (8) 381-390
• 15 Howes OD, Kambeitz J, Kim E , et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry 2012; 69 (8) 776-786
• 16 Ito M, Nagai T, Mizoguchi H , et al. Activation of post-synaptic dopamine D₁ receptors promotes the release of tissue plasminogen activator in the nucleus accumbens via PKA signaling. J Neurochem 2007; 103 (6) 2589-2596
• 17 Nurjono M, Lee J, Chong SA. A review of brain-derived neurotrophic factor as a candidate biomarker in schizophrenia. Clin Psychopharmacol Neurosci 2012; 10 (2) 61-70
• 18 Chen C, Wang J, Wang B , et al. Decreased levels of serum brain-derived neurotrophic factor in drug-naive first-episode schizophrenia: relationship to clinical phenotypes. Psychopharmacology (Berl) 2009; 207 (3) 375-380
• 19 Lu B, Martinowich K. Cell biology of BDNF and its relevance to schizophrenia. Novartis Found Symp 2008; 289: 119-129 , discussion 129–135, 193–195
• 20 Cavaletti G, Slusher B. Regulation of glutamate synthesis via inhibition of glutamate carboxypeptidase II (GCPII): an effective method to treat central and peripheral nervous system disorders. Curr Med Chem 2012; 19 (9) 1259-1260
• 21 Driesen NR, McCarthy G, Bhagwagar Z , et al. Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans. Mol Psychiatry 2013; ; doi: 10.1038/mp.2012.194
• 22 Torrey EF, Barci BM, Webster MJ, Bartko JJ, Meador-Woodruff JH, Knable MB. Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains. Biol Psychiatry 2005; 57 (3) 252-260
• 23 Yuan H, Vance KM, Junge CE , et al. The serine protease plasmin cleaves the amino-terminal domain of the NR2A subunit to relieve zinc inhibition of the N-methyl-D-aspartate receptors. J Biol Chem 2009; 284 (19) 12862-12873
• 24 Wu F, Echeverry R, Wu J , et al. Tissue-type plasminogen activator protects neurons from excitotoxin-induced cell death via activation of the ERK1/2-CREB-ATF3 signaling pathway. Mol Cell Neurosci 2013; 52: 9-19
• 25 Cassé F, Bardou I, Danglot L , et al. Glutamate controls tPA recycling by astrocytes, which in turn influences glutamatergic signals. J Neurosci 2012; 32 (15) 5186-5199
• 26 Diez H, Garrido JJ, Wandosell F. Specific roles of Akt iso forms in apoptosis and axon growth regulation in neurons. PLoS ONE 2012; 7 (4) e32715
• 27 Echeverry R, Wu J, Haile WB, Guzman J, Yepes M. Tissue-type plasminogen activator is a neuroprotectant in the mouse hippocampus. J Clin Invest 2010; 120 (6) 2194-2205
• 28 Levine J, Stahl Z, Sela BA , et al. Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. Biol Psychiatry 2006; 60 (3) 265-269
• 29 Muntjewerff JW, Kahn RS, Blom HJ, den Heijer M. Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis. Mol Psychiatry 2006; 11 (2) 143-149
• 30 James SJ, Melnyk S, Pogribna M, Pogribny IP, Caudill MA. Elevation in S-adenosylhomocysteine and DNA hypomethylation: potential epigenetic mechanism for homocysteine-related pathology. J Nutr 2002; 132 (8) (Suppl): 2361S-2366S
• 31 Grayson DR, Jia X, Chen Y , et al. Reelin promoter hypermethylation in schizophrenia. Proc Natl Acad Sci U S A 2005; 102 (26) 9341-9346
• 32 Hajjar KA, Mauri L, Jacovina AT , et al. Tissue plasminogen activator binding to the annexin II tail domain. Direct modulation by homocysteine. J Biol Chem 1998; 273 (16) 9987-9993
• 33 Campo CG, Sinagra M, Verrier D, Manzoni OJ, Chavis P. Reelin secreted by GABAergic neurons regulates glutamate receptor homeostasis. PLoS ONE 2009; 4 (5) e5505
• 34 Reif A, Schmitt A, Fritzen S, Lesch KP. Neurogenesis and schizophrenia: dividing neurons in a divided mind?. Eur Arch Psychiatry Clin Neurosci 2007; 257 (5) 290-299
• 35 Jossin Y, Gui L, Goffinet AM. Processing of Reelin by embryonic neurons is important for function in tissue but not in dissociated cultured neurons. J Neurosci 2007; 27 (16) 4243-4252
• 36 Seeds NW, Basham ME, Haffke SP. Neuronal migration is retarded in mice lacking the tissue plasminogen activator gene. Proc Natl Acad Sci U S A 1999; 96 (24) 14118-14123
• 37 Saddichha S, Manjunatha N, Ameen S, Akhtar S. Diabetes and schizophrenia - effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia. Acta Psychiatr Scand 2008; 117 (5) 342-347
• 38 Liu Y, Li Z, Zhang M, Deng Y, Yi Z, Shi T. Exploring the pathogenetic association between schizophrenia and type 2 diabetes mellitus diseases based on pathway analysis. BMC Med Genomics 2013; 6 (Suppl. 01) S17
• 39 Hansen T, Ingason A, Djurovic S , et al. At-risk variant in TCF7L2 for type II diabetes increases risk of schizophrenia. Biol Psychiatry 2011; 70 (1) 59-63
• 40 Alkelai A, Greenbaum L, Lupoli S , et al. Association of the type 2 diabetes mellitus susceptibility gene, TCF7L2, with schizophrenia in an Arab-Israeli family sample. PLoS ONE 2012; 7 (1) e29228
• 41 Nordt TK, Sawa H, Fujii S, Sobel BE. Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation 1995; 91 (3) 764-770
• 42 Myles N, Newall HD, Curtis J, Nielssen O, Shiers D, Large M. Tobacco use before, at, and after first-episode psychosis: a systematic meta-analysis. J Clin Psychiatry 2012; 73 (4) 468-475
• 43 de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res 2005; 76 (2-3) 135-157
• 44 Nagai T, Ito M, Nakamichi N , et al. The rewards of nicotine: regulation by tissue plasminogen activator-plasmin system through protease activated receptor-1. J Neurosci 2006; 26 (47) 12374-12383
• 45 Kumari V, Postma P. Nicotine use in schizophrenia: the self medication hypotheses. Neurosci Biobehav Rev 2005; 29 (6) 1021-1034
• 46 Smith RC, Warner-Cohen J, Matute M , et al. Effects of nicotine nasal spray on cognitive function in schizophrenia. Neuropsychopharmacology 2006; 31 (3) 637-643
• 47 Mortensen PB. The incidence of cancer in schizophrenic patients. J Epidemiol Community Health 1989; 43 (1) 43-47
• 48 Cohen ME, Dembling B, Schorling JB. The association between schizophrenia and cancer: a population-based mortality study. Schizophr Res 2002; 57 (2-3) 139-146
• 49 Hodgson R, Wildgust HJ, Bushe CJ. Cancer and schizophrenia: is there a paradox?. J Psychopharmacol 2010; 24 (4) (Suppl): 51-60
• 50 Lichtermann D, Ekelund J, Pukkala E, Tanskanen A, Lönnqvist J. Incidence of cancer among persons with schizophrenia and their relatives. Arch Gen Psychiatry 2001; 58 (6) 573-578
• 51 Rakic JM, Maillard C, Jost M , et al. Role of plasminogen activator-plasmin system in tumor angiogenesis. Cell Mol Life Sci 2003; 60 (3) 463-473